Shares of Caplin Point Laboratories surged by 6%, reflecting strong market sentiment driven by technical momentum. This rise comes after shareholders approved the appointment of R. Vijayaraghavan as an Independent Director for a five-year term during the Annual General Meeting (AGM) held on September 30.
The boost in the company’s stock value highlights positive investor reactions to this development and adds confidence for those looking to buy shares online.
The expertise of R. Vijayaraghavan
R. Vijayaraghavan, a taxation expert with over 35 years of experience, has made significant contributions to corporate tax consulting and litigation in India, particularly in the southern region. With his extensive background, he has advised leading corporate groups on matters related to Direct Taxes, Tax Planning, and Tax Litigation.
His appointment is expected to strengthen Caplin Point Laboratories' strategic approach, offering a solid foundation for investors, especially those looking to buy shares online in a stable and growing company.
Caplin’s technical strength on the stock market
According to technical analysis, Caplin Point Laboratories is showing a strong bullish trend on daily charts, with firm support at ₹1,874. A close above the key resistance level of ₹1,980 could lead to future price targets between ₹2,148 and ₹2,316.
This upward trajectory makes it an attractive option for investors who plan to buy shares online as the stock continues to outperform market expectations.
Strong performance on the National Stock Exchange
At 9:44 a.m. on the day of the report, Caplin Point shares were trading at ₹1,995, marking a gain of over 5% on the National Stock Exchange (NSE). Over the past year, the stock has seen a substantial 47% increase, far exceeding the Nifty’s 18% return in the same period.
The remarkable performance of Caplin Point makes it an appealing stock for investors looking to buy shares online in a company with a proven track record of growth.
Year-on-year growth and market leadership
In the last 12 months, Caplin Point Laboratories has delivered a 90% return to its shareholders, almost doubling their investments. By comparison, the Nifty index saw a rise of only 32% during the same period. Such exceptional growth reinforces the company's position as a top choice for those wanting to buy shares online and benefit from Caplin’s ongoing market leadership.
Successful inspection by the Brazilian Health Regulatory Agency
In August 2024, the Brazilian Health Regulatory Agency (ANVISA) completed an inspection of Caplin Steriles’ manufacturing facility at Gummidipoondi. The facility, which produces injectables and ophthalmic products, passed the inspection with zero observations.
This achievement is critical for Caplin's expansion into the Latin American market, particularly Brazil, which represents a key area for future growth. The company’s clean audit further strengthens its reputation for high compliance standards, making it a reliable option for those interested in buying shares online.
Commitment to quality and growth
Commenting on the successful inspection, Caplin Point Laboratories Chairman C.C. Paarthipan emphasised the company's unwavering commitment to maintaining high-quality standards. "It is indeed gratifying to have two back-to-back audits with zero observations," he said.
Caplin’s focus on excellence and compliance in its operations positions it as a solid investment opportunity for individuals planning to buy shares online in a company poised for continued growth and success.
For android only